<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101370</url>
  </required_header>
  <id_info>
    <org_study_id>BOZ-501</org_study_id>
    <nct_id>NCT04101370</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects</brief_title>
  <official_title>Two-way Crossover, Open-label, Single-dose, Bioequivalence Study of Bosentan (LLC &quot;GEROPHARM&quot;, Russia) 125 mg Tablets Immediate Release (IR )Versus Tracleer® (Actelion Pharmaceuticals Ltd., Switzerland) 125 mg Tablets IR in Normal Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer®
      Actelion)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate
      release tablets, 125 mg in normal healthy subjects under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.</time_frame>
    <description>Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.</time_frame>
    <description>Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tracleer®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan 125 mg</intervention_name>
    <description>Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>bosentan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tracleer 125Mg Tablet</intervention_name>
    <description>Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition</description>
    <arm_group_label>Tracleer®</arm_group_label>
    <other_name>bosentan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Healthy male aged 18 to 45 years.

          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and
             Instrumental methods of examination.

          -  Have a body mass index between 18,5 and 30 kg/m2.

          -  Subjects must use, with their partner, methods of highly effective contraception
             throughout the study and 30 days after the end of study.

          -  Ability to keep fasting state for at least 14 hours.

          -  Consent and ability to respect the schedule of visits and the points of the Protocol.

        Exclusion Criteria:

          -  History of serious allergic problems/events.

          -  Medicinal intolerance.

          -  Any acute and chronic diseases of the cardiovascular system, cardiovascular,
             bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal
             tract, liver, kidneys, blood.

          -  Psychiatric disorders, history of epilepsy and seizures.

          -  Acute infectious diseases in less than 4 weeks before the start of the study.

          -  Subjects who have taken medication 2 weeks preceding before the study.

          -  Subjects who have taken any drugs known effects on hemodynamics or to induce or
             inhibit hepatic drug metabolism within 30 days prior to administration of the study
             medication (examples of inducers: barbiturates, omeprazole, etc.).

          -  Donation of plasma (450 mL or more) within 2 month prior to administration of the
             study medication.

          -  History of significant alcohol or drugs abuse or any indication of the regular use of
             more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or
             50 mL of alcohol 40%).

          -  Smokers.

          -  Participation in other clinical training is less than than for 3 months before the
             study.

          -  Lack of signed informed consent form.

          -  10% deviation from references in lab tests.

          -  Positive testing for alcohol, drugs.

          -  Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before
             the start of the study.

          -  Any diet (vegetarian, etc.) extreme physical exercise, night shift work.

          -  Heart rate below 60 or above 80 beats per minute.

          -  Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.

          -  Diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.

          -  Volunteers, for Investigator opinion, who can not understand and evaluate the
             information about this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Hospital № 3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>bosentan</keyword>
  <keyword>fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

